MAPK Pathway Inhibitors Augment Treatments for Pediatric Low-Grade Gliomas
MAPK Pathway Inhibitors Augment Treatments for Pediatric Low-Grade Gliomas is organized by Physicians' Education Resource, LLC (PER).
Release Date: May 5, 2023
Expiration Date: May 5, 2024
Description:
Low-grade gliomas are a common type of central nervous system tumor in pediatric oncology. This subtype deviates significantly from high-grade gliomas, especially with the notable objective of being able to achieve excellent outcomes in patients. Education to enhance knowledge and awareness of treatment modalities and new approvals of targeted therapeutics is an important component to further improve outcomes. Kenneth Cohen, MD, MBA, is a pediatric oncologist and the Director of the Pediatric Neuro-Oncology program in the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. In this article, he will discuss the role that genomic technology has had on the field, including the identification of a predisposition syndrome and the discovery of BRAF mutations in gliomas. He also gives insight into his approach to disease treatment in patients and makes predictions about what he believes the future holds.
Learning Objectives:
Upon successful completion of this activity, you should be better prepared to:
• Explain the impact of genomic technologies on pediatric low-grade glioma and how interrogating tumor tissue applies to current therapeutics
• Assess modalities implemented in pediatric low-grade glioma and the goals of treatment with the rationale for why these may or may not be used
• Outline a communication approach for parents of patients with low-grade glioma concerning disease treatment and clinical trial participation.